News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Subscribe To Our Newsletter & Stay Updated
